<DOC>
	<DOCNO>NCT00000666</DOCNO>
	<brief_summary>To evaluate pyrimethamine prophylactic agent toxoplasmic encephalitis individual coinfected HIV latent Toxoplasma gondii . Toxoplasmic encephalitis major cause illness death AIDS patient . Standard treatment toxoplasmic encephalitis combine pyrimethamine sulfadiazine . Continuous treatment necessary prevent recurrence disease , constant use pyrimethamine/sulfadiazine associate toxicity . Clindamycin show effective treatment toxoplasmic encephalitis animal study . This study evaluate pyrimethamine preventive treatment toxoplasmic encephalitis ( per 3/26/91 amendment , clindamycin arm discontinue ) .</brief_summary>
	<brief_title>A Randomized Prospective Study Pyrimethamine Therapy Prevention Toxoplasmic Encephalitis HIV-Infected Individuals With Serologic Evidence Latent Toxoplasma Gondii Infection</brief_title>
	<detailed_description>Toxoplasmic encephalitis major cause illness death AIDS patient . Standard treatment toxoplasmic encephalitis combine pyrimethamine sulfadiazine . Continuous treatment necessary prevent recurrence disease , constant use pyrimethamine/sulfadiazine associate toxicity . Clindamycin show effective treatment toxoplasmic encephalitis animal study . This study evaluate pyrimethamine preventive treatment toxoplasmic encephalitis ( per 3/26/91 amendment , clindamycin arm discontinue ) . Patients randomize receive pyrimethamine placebo three time week . All patient must aerosolize pentamidine , trimethoprim / sulfamethoxazole ( T/S ) , dapsone Pneumocystis carinii pneumonia prophylaxis . Patients evaluate bi-weekly first month every month thereafter least 24 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis , Cerebral</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Prophylactic treatment Pneumocystis carinii pneumonia aerosolize pentamidine , dapsone , trimethoprim / sulfamethoxazole . Allowed : Most medication specifically exclude . Prior Medication : Allowed : Antivirals . Antiretrovirals . Patients : Must HIV positive AIDSdefining illness OR know risk HIV infection CD4 cell count &lt; 200/mm3 know immunosuppressive disease . Must positive titer Toxoplasma gondii . Must become patient CPCRA physician . May participate clinical trial long potential activity Toxoplasma gondii crosstoxicity among study drug . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : History ocular , pulmonary , central nervous system ( CNS ) toxicity . CNS lesion . Neurologic deficits except peripheral neuropathy . Mild , moderate , severe , endstage AIDS dementia complex . Grade 3 high nausea and/or vomit . Sensitivity pyrimethamine . Concurrent Medication : Excluded : Ongoing therapy clindamycin , fansidar , methotrexate , trimetrexate , spiramycin , azithromycin , clarithromycin , 566C80 , and/or sulfa agent antiPCP agent . Patients follow excluded : History ocular , pulmonary , central nervous system ( CNS ) toxicity . CNS lesion history CNS lesion . Neurologic deficits except peripheral neuropathy . Mild , moderate , severe , endstage AIDS dementia complex . Grade 3 high nausea and/or vomit . Sensitivity pyrimethamine .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Toxoplasmosis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pyrimethamine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>